9606 — Duality Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- HK$20.73bn
- HK$17.00bn
- CNY1.85bn
Annual income statement for Duality Biotherapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 1,787 | 1,941 | 1,852 |
| Cost of Revenue | |||
| Gross Profit | 1,359 | 785 | 589 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 1,005 | 2,130 | 2,339 |
| Operating Profit | 781 | -189 | -487 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -202 | -1,015 | -2,595 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -358 | -1,050 | -2,595 |
| Net Income Before Extraordinary Items | |||
| Net Income | -358 | -1,050 | -2,595 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -358 | -1,050 | -2,595 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -4.3 | -12.3 | -28.6 |